Persistence with first-line antihypertensives poor in Italy

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.494, 2006-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Persistence with first-line antihypertensives poor in Italy

By  

Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

What are the best first-line antihypertensives: answers and more questions from the ALLHAT study

By Salam Amar Mohammad  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 5, 2003-05 ,pp. : 879-885

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis

By Ravasio Roberto   Ortega Cinzia   Sabbatini Roberto   Porta Camillo  

Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. : 507-517

Adis International

Access to resources Recommend Favorite

Efavirenz – Still First-line King?

By Best Brookie M   Goicoechea Miguel  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 7, 2008-07 ,pp. : 965-972

Informa Healthcare

Access to resources Recommend Favorite

Adverse reactions to first-line antituberculosis drugs

By Forget Eric J   Menzies Dick  

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 231-249

Informa Healthcare

Access to resources Recommend Favorite